 Today I have the pleasure of speaking with the new CEO for Med-Ex Health, Naman. How are you today? Very good, Tracy. Thanks for having me on. You've barely been the CEO for one week when we have outstanding news just put out. You've got a commercial distribution agreement with Vitamed Biomedical. Let's start there. Absolutely, Tracy. We're really excited. Although I've been the CEO for just a week of Med-Ex, I have been managing the European Theater Europe, Middle East and Africa now for about a year and a half. Tracy, this is a result of about a year's work and a new methodology that I put in when I arrived in the region of testing out the market and the partner rather than the technology that we know works very well. And what we did was we put in a number of pilots in the European Theater that have matured and Vitamed in Italy is the first one that will be going to a full commercial contract. So the timing was really very, very good for me. Obviously, as I arrived to see the fruition of my work over the last year, year and a half in the European Theater, and I'm looking forward to expanding this globally to all the markets that Med-Ex is looking at currently. Well, and just to back you up, you really weren't appointed new CEO. It was basically a promotion. You've been a director. Is that not correct? You're head of International Sales predominantly. You were involved in that big European deal in England. Is that correct? Yes, correct. The Health Partners deal is one of the deals that I've been working on in the region, along with the deals that were done in the Middle East with the Al-Zahrawi group in Dubai and in Saudi Arabia, along with a team member that I recruited for the region to manage Africa and the Middle East. So yes, it has been a wonderful promotion and I'm really happy to be able to continue the work at this higher level. Many of us have been following Med-Ex Health for the last several years ever since we were introduced to the idea that you were focused. The company's been focused on becoming a global leader in teledermatology. Tell us more about how you're going to take that vision forward. Absolutely. So the idea over here really is to focus on one of the most dangerous life-threatening indications, which is pigmented lesions and melanoma. That is what we have been able to do through our sciastopy technology, which is unique in the world. But also we want to grow our offering across indications to other skin conditions. So we will be launching very closely a camera, an HD camera, that will be adapted to our DermSecure platform and offer that to our existing client-based as well as our new clients. The vision is to not only lead the market in technology, but also in information and in data. A lot of these customers are giving us valuable data through the scans that we are currently collecting that will in the future be able to be used for research and development in the field of dermatology. Well, Neman, thank you so much for joining us today and for everybody out there at Investor Intel Land. I know you care about revenue. I urge you to read this news release. Neman, we're going to have you on very regularly. Again, thank you for joining us today. Congratulations on your new position as CEO. Thank you, Tracy. Thank you for having me. We're very excited.